28234672|t|Vascular smooth muscle cell peroxisome proliferator-activated receptor γ protects against endothelin-1 - induced oxidative stress and inflammation
28234672|a|Peroxisome proliferator-activated receptor γ (PPARγ) agonists reduce blood pressure and vascular injury in hypertensive rodents. Pparγ inactivation in vascular smooth muscle cells (VSMC) enhances vascular injury. Transgenic mice overexpressing endothelin (ET)-1 selectively in the endothelium (eET-1) exhibit endothelial dysfunction, increased oxidative stress and inflammation. We hypothesized that inactivation of the Pparγ gene in VSMC (smPparγ) would exaggerate ET-1 - induced vascular injury. eET-1, smPparγ and eET-1 / smPparγ mice were treated with tamoxifen for 5 days and studied 4 weeks later. SBP was higher in eET-1 and unaffected by smPparγ inactivation. Mesenteric artery vasodilatory responses to acetylcholine were impaired only in smPparγ. N-Nitro-L-arginine methyl ester abrogated relaxation responses, and the Ednra / Ednrb mRNA ratio was decreased in eET-1 / smPparγ, which could indicate that nitric oxide production was enhanced by ET-1 stimulation of endothelin type B receptors. Mesenteric artery media / lumen was greater only in eET-1 / smPparγ. Mesenteric artery reactive oxygen species increased in smPparγ and were further enhanced in eET-1 / smPparγ. Perivascular fat monocyte / macrophage infiltration was higher in eET-1 and smPparγ and increased further in eET-1 / smPparγ. Spleen CD11b cells were increased in smPparγ and further enhance d in eET-1 / smPparγ, whereas Ly-6C monocytes increased in eET-1 and smPparγ but not in eET-1 / smPparγ. Spleen T regulatory lymphocytes increased in smPparγ and decreased in eET-1, and decreased further in eET-1 / smPparγ. VSMC Pparγ inactivation exaggerates ET-1 - induced vascular injury, supporting a protective role for PPARγ in hypertension through modulation of pro-oxidant and proinflammatory pathways. Paradoxically, ET-1 overexpression preserved endothelial function in smPparγ mice, presumably by enhancing nitric oxide through stimulation of endothelin type B receptors.
28234672	0	27	Vascular smooth muscle cell	T017	UMLS:C4082861
28234672	28	72	peroxisome proliferator-activated receptor γ	T103	UMLS:C0166417
28234672	90	102	endothelin-1	T103	UMLS:C0079281
28234672	113	129	oxidative stress	T038	UMLS:C0242606
28234672	134	146	inflammation	T038	UMLS:C0021368
28234672	147	191	Peroxisome proliferator-activated receptor γ	T103	UMLS:C0166417
28234672	193	198	PPARγ	T103	UMLS:C0166417
28234672	200	208	agonists	T103	UMLS:C0243192
28234672	216	230	blood pressure	T038	UMLS:C0005823
28234672	235	250	vascular injury	T037	UMLS:C0178324
28234672	254	266	hypertensive	T033	UMLS:C0857121
28234672	267	274	rodents	T204	UMLS:C0035804
28234672	276	281	Pparγ	T103	UMLS:C0166417
28234672	282	294	inactivation	T038	UMLS:C0314679
28234672	298	326	vascular smooth muscle cells	T017	UMLS:C4082861
28234672	328	332	VSMC	T017	UMLS:C4082861
28234672	343	358	vascular injury	T037	UMLS:C0178324
28234672	360	375	Transgenic mice	T204	UMLS:C0025936
28234672	376	390	overexpressing	T038	UMLS:C1171362
28234672	391	408	endothelin (ET)-1	T103	UMLS:C0079281
28234672	428	439	endothelium	T017	UMLS:C0014257
28234672	440	447	(eET-1)	T103	UMLS:C0079281
28234672	456	479	endothelial dysfunction	T038	UMLS:C0856169
28234672	491	507	oxidative stress	T038	UMLS:C0242606
28234672	512	524	inflammation	T038	UMLS:C0021368
28234672	547	559	inactivation	T038	UMLS:C0314679
28234672	567	577	Pparγ gene	T017	UMLS:C1335238
28234672	581	585	VSMC	T017	UMLS:C4082861
28234672	587	594	smPparγ	T017	UMLS:C1335238
28234672	613	617	ET-1	T103	UMLS:C0079281
28234672	628	643	vascular injury	T037	UMLS:C0178324
28234672	645	650	eET-1	T103	UMLS:C0079281
28234672	652	659	smPparγ	T103	UMLS:C0166417
28234672	664	669	eET-1	T103	UMLS:C0079281
28234672	672	679	smPparγ	T103	UMLS:C0166417
28234672	680	684	mice	T204	UMLS:C0025929
28234672	690	697	treated	T033	UMLS:C0332154
28234672	703	712	tamoxifen	T103	UMLS:C0039286
28234672	728	735	studied	T062	UMLS:C2603343
28234672	751	754	SBP	T201	UMLS:C0871470
28234672	769	774	eET-1	T103	UMLS:C0079281
28234672	793	800	smPparγ	T103	UMLS:C0166417
28234672	801	813	inactivation	T038	UMLS:C0314679
28234672	815	832	Mesenteric artery	T017	UMLS:C0025465
28234672	833	845	vasodilatory	T038	UMLS:C0042401
28234672	859	872	acetylcholine	T103	UMLS:C0001041
28234672	895	902	smPparγ	T103	UMLS:C0166417
28234672	904	935	N-Nitro-L-arginine methyl ester	T103	UMLS:C0083536
28234672	976	981	Ednra	T017	UMLS:C1414262
28234672	984	989	Ednrb	T017	UMLS:C1414263
28234672	990	994	mRNA	T103	UMLS:C0035696
28234672	1018	1023	eET-1	T103	UMLS:C0079281
28234672	1026	1033	smPparγ	T103	UMLS:C0166417
28234672	1061	1073	nitric oxide	T103	UMLS:C0028128
28234672	1101	1105	ET-1	T103	UMLS:C0079281
28234672	1121	1148	endothelin type B receptors	T103	UMLS:C0218584
28234672	1150	1167	Mesenteric artery	T017	UMLS:C0025465
28234672	1202	1207	eET-1	T103	UMLS:C0079281
28234672	1210	1217	smPparγ	T103	UMLS:C0166417
28234672	1219	1236	Mesenteric artery	T017	UMLS:C0025465
28234672	1237	1260	reactive oxygen species	T103	UMLS:C0162772
28234672	1274	1281	smPparγ	T103	UMLS:C0166417
28234672	1311	1316	eET-1	T103	UMLS:C0079281
28234672	1319	1326	smPparγ	T103	UMLS:C0166417
28234672	1328	1340	Perivascular	T082	UMLS:C0442165
28234672	1341	1353	fat monocyte	T017	UMLS:C0206131
28234672	1356	1366	macrophage	T017	UMLS:C0024432
28234672	1367	1379	infiltration	T038	UMLS:C0332448
28234672	1394	1399	eET-1	T103	UMLS:C0079281
28234672	1404	1411	smPparγ	T103	UMLS:C0166417
28234672	1437	1442	eET-1	T103	UMLS:C0079281
28234672	1445	1452	smPparγ	T103	UMLS:C0166417
28234672	1454	1460	Spleen	T017	UMLS:C0037993
28234672	1491	1498	smPparγ	T103	UMLS:C0166417
28234672	1524	1529	eET-1	T103	UMLS:C0079281
28234672	1532	1539	smPparγ	T103	UMLS:C0166417
28234672	1549	1564	Ly-6C monocytes	T017	UMLS:C0440752
28234672	1578	1583	eET-1	T103	UMLS:C0079281
28234672	1588	1595	smPparγ	T103	UMLS:C0166417
28234672	1607	1612	eET-1	T103	UMLS:C0079281
28234672	1615	1622	smPparγ	T103	UMLS:C0166417
28234672	1624	1630	Spleen	T017	UMLS:C0037993
28234672	1631	1655	T regulatory lymphocytes	T017	UMLS:C0039198
28234672	1669	1676	smPparγ	T103	UMLS:C0166417
28234672	1694	1699	eET-1	T103	UMLS:C0079281
28234672	1726	1731	eET-1	T103	UMLS:C0079281
28234672	1734	1741	smPparγ	T103	UMLS:C0166417
28234672	1743	1747	VSMC	T017	UMLS:C4082861
28234672	1748	1753	Pparγ	T103	UMLS:C0166417
28234672	1754	1766	inactivation	T038	UMLS:C0314679
28234672	1779	1783	ET-1	T103	UMLS:C0079281
28234672	1794	1809	vascular injury	T037	UMLS:C0178324
28234672	1844	1849	PPARγ	T103	UMLS:C0166417
28234672	1853	1865	hypertension	T038	UMLS:C0020538
28234672	1874	1884	modulation	T082	UMLS:C0443264
28234672	1888	1899	pro-oxidant	T103	UMLS:C0162772
28234672	1920	1928	pathways	T038	UMLS:C1704259
28234672	1945	1949	ET-1	T103	UMLS:C0079281
28234672	1950	1964	overexpression	T038	UMLS:C1171362
28234672	1975	1986	endothelial	T017	UMLS:C0014257
28234672	1999	2006	smPparγ	T103	UMLS:C0166417
28234672	2007	2011	mice	T204	UMLS:C0025929
28234672	2037	2049	nitric oxide	T103	UMLS:C0028128
28234672	2073	2100	endothelin type B receptors	T103	UMLS:C0218584